Open AccessEnhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review
Author(s) -
Shane Mesko,
Gottfried E. Konecny,
Paul C. Tumeh,
Mitchell Kamrava
Publication year - 2017
Publication title -
bjr case reports
Language(s) - English
Resource type - Journals
ISSN - 2055-7159
DOI - 10.1259/bjrcr.20160002
Subject(s) - ipilimumab , medicine , desquamation , radiation therapy , dermatology , melanoma , toxicity , immunotherapy , cytotoxic t cell , oncology , cancer research , cancer , biology , biochemistry , in vitro
Ipilimumab is a monoclonal cytotoxic T-lymphocyte-associated protein 4 antibody that has demonstrated improved survival in cutaneous melanoma. Little is known about the clinical impact of combining anti-cytotoxic T-lymphocyteassociated protein 4 therapy with radiation. Here we report a case of severe cutaneous desquamation in a 70-year-old female with vaginal/vulvar melanoma receiving concurrent ipilimumab and radiation therapy. The toxicity was successfully treated with oral/topical steroids and a break from treatment. This case underscores the importance of future research on optimal strategies for combining radiation with novel anti-tumour agents.